Profile data is unavailable for this security.
About the company
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
- Revenue in USD (TTM)510.17m
- Net income in USD146.93m
- Incorporated2006
- Employees647.00
- LocationADMA Biologics Inc465 State Route 17RAMSEY 07446United StatesUSA
- Phone+1 (201) 478-5552
- Fax+1 (201) 478-5553
- Websitehttps://www.admabiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 1.00bn | 22.39m | 2.65bn | 733.00 | 167.64 | 7.08 | 110.50 | 2.64 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Liquidia Corp | 69.22m | -121.85m | 2.69bn | 157.00 | -- | 121.81 | -- | 38.89 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.81bn | 979.00 | -- | 6.17 | -- | 7.19 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.18 | 3.07 | 11.56 | 4.95 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 3.07bn | 354.00 | -- | 16.12 | -- | 8.17 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.17bn | 674.00 | -- | 2.98 | 59.59 | 4.40 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.24bn | 600.00 | 18.12 | 1.77 | 14.97 | 2.94 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.30bn | 370.00 | -- | 9.59 | -- | 7.30 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.52bn | 366.00 | 61.76 | 6.18 | 58.14 | 5.20 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.83bn | 730.00 | 43.32 | 5.88 | 37.96 | 5.03 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.95bn | 647.00 | 27.65 | 8.26 | 25.47 | 7.74 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 4.00bn | 1.03k | 33.34 | -- | 27.02 | 3.39 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.04bn | 68.00 | 97.48 | 4.19 | 48.79 | 16.08 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.33bn | 8.10k | 833.54 | -- | 14.53 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.69bn | 399.00 | 10.59 | 7.05 | 10.50 | 7.62 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.44bn | 369.00 | -- | 14.86 | 6,170.46 | 10.43 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
Data as of Mar 03 2026. Currency figures normalised to ADMA Biologics Inc's reporting currency: US Dollar USD
48.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 33.36m | 14.02% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 18.88m | 7.93% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 13.60m | 5.71% |
| Sachem Head Capital Management LPas of 31 Dec 2025 | 11.38m | 4.78% |
| Invesco Advisers, Inc.as of 31 Dec 2025 | 9.43m | 3.96% |
| Westfield Capital Management Co. LPas of 31 Dec 2025 | 6.99m | 2.94% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 6.64m | 2.79% |
| Geode Capital Management LLCas of 31 Dec 2025 | 5.83m | 2.45% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 5.20m | 2.18% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 4.60m | 1.93% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
